Zacks Investment Research on MSN
NVO's first oral obesity pill approval: What does it mean for Lilly?
Earlier this week, the FDA approved Eli Lilly and Company’s LLY rival Novo Nordisk’s NVO oral version of the obesity drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback